12.2
Dosage Regimens: Partial Pharmacokinetic Parameters
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by…
The complete pharmacokinetic profiles of many drugs are often unknown or unavailable.
So, researchers need to make a few assumptions to calculate dosage regimens without pharmacokinetic data, depending on the drug's safety, efficacy, and therapeutic range.
One common assumption is setting the bioavailability factor, F, to 1 or 100%.
This ensures that if a drug is not fully absorbed, patients are undermedicated rather than overmedicated.
Population pharmacokinetics uses the average patient population characteristics with limited serum drug concentration samples from patients.
Population pharmacokinetics’ use in therapeutic drug monitoring has increased due to the availability of computerized databases and the development of statistical tools for observational data analysis.
View the full transcript and gain access to JoVE Core videos
Q1: Why do researchers set the bioavailability factor to 1 when complete pharmacokinetic data is unavailable?
Setting the bioavailability factor, F, to 1 or 100% ensures that if a drug is not fully absorbed, patients are undermedicated rather than overmedicated. This conservative assumption prioritizes patient safety by erring on the side of caution when complete pharmacokinetic profiles remain unknown or unavailable.
Q2: What factors guide the selection of assumptions for dosage regimen calculations?
Pharmacokineticists select assumptions based on three key factors: the drug's safety profile, its efficacy, and its therapeutic range. These criteria ensure that educated assumptions about bioavailability and other parameters lead to appropriate dosage regimens that balance therapeutic effectiveness with patient protection.
Q3: How does population pharmacokinetics help when individual drug data is incomplete?
Population pharmacokinetics uses average patient population characteristics combined with limited serum drug concentration samples from patients to estimate dosing parameters. This approach has increased in therapeutic drug monitoring due to computerized databases and advanced statistical tools for analyzing observational data.
Q4: What role do computerized databases play in modern dosage regimen development?
Computerized databases enable population pharmacokinetics by storing and organizing large amounts of patient data and serum drug concentration information. Combined with statistical tools for observational data analysis, these databases facilitate the calculation of appropriate dosage regimens without requiring complete individual pharmacokinetic profiles.
Q5: Why is population pharmacokinetics increasingly used in therapeutic drug monitoring?
Population pharmacokinetics has gained prominence in therapeutic drug monitoring because it provides a practical alternative when complete pharmacokinetic profiles are unavailable. The availability of computerized databases and development of statistical tools for observational data analysis make this approach feasible and reliable for clinical practice.
Q6: What happens if a drug's bioavailability assumption is set too high?
If the bioavailability factor is set too high, patients may receive insufficient drug doses, resulting in undermedication and reduced therapeutic effectiveness. This is why researchers conservatively set F to 1 or 100% when complete absorption data is unknown, prioritizing patient safety over potential overmedication risks.
Q7: How do statistical tools support dosage regimen calculations in population pharmacokinetics?
Statistical tools designed for observational data analysis enable pharmacokineticists to extract meaningful pharmacokinetic information from limited serum drug concentration samples across patient populations. These tools help calculate reliable dosage regimens by identifying patterns and relationships in population-level data when individual complete profiles are unavailable.